89bio initiates phase 3 enlighten-cirrhosis trial of pegozafermin in metabolic dysfunction-associated steatohepatitis (mash) patients with compensated cirrhosis

—with the initiation of enlighten-cirrhosis, pegozafermin is the first fgf21 analog to enter a phase 3 trial in mash patients with compensated cirrhosis (f4)—

ETNB Ratings Summary

ETNB Quant Ranking